- Home
- WRBY vs NAMS Comparison
WRBY vs NAMS Comparison
Compare WRBY & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | NAMS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | WRBY | NAMS |
|---|---|---|
| Price | $22.58 | $34.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $26.50 | ★ $47.38 |
| AVG Volume (30 Days) | ★ 2.8M | 584.0K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | $35,243,000.00 |
| Revenue This Year | $15.66 | N/A |
| Revenue Next Year | $12.88 | $11.19 |
| P/E Ratio | $3,826.81 | ★ N/A |
| Revenue Growth | ★ 14.55 | 4.91 |
| 52 Week Low | $13.63 | $14.06 |
| 52 Week High | $31.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | WRBY | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 58.24 |
| Support Level | $20.89 | $33.14 |
| Resistance Level | $25.76 | $35.61 |
| Average True Range (ATR) | 1.79 | 1.40 |
| MACD | -0.66 | 0.43 |
| Stochastic Oscillator | 7.28 | 94.24 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.